Company profile SGMO

Sangamo Therapeutics Inc
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human gen...ome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com. Show More
Quarter analysis & expected interest

There is not enough data for Sangamo Therapeutics near me to provide analysis

Correlation between past revenue and Sangamo Therapeutics near me search interest

There is not enough data for Sangamo Therapeutics near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Sangamo Therapeutics near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Sangamo Therapeutics login to provide analysis

Correlation between past revenue and Sangamo Therapeutics login search interest

There is not enough data for Sangamo Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Sangamo Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Sangamo Therapeutics careers to provide analysis

Correlation between past revenue and Sangamo Therapeutics careers search interest

There is not enough data for Sangamo Therapeutics careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Sangamo Therapeutics careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Sangamo Therapeutics gene therapy to provide analysis

Correlation between past revenue and Sangamo Therapeutics gene therapy search interest

There is not enough data for Sangamo Therapeutics gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Sangamo Therapeutics gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ST-920 clinical study to provide analysis

Correlation between past revenue and ST-920 clinical study search interest

There is not enough data for ST-920 clinical study to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ST-920 clinical study to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TX200 CAR-Treg therapy to provide analysis

Correlation between past revenue and TX200 CAR-Treg therapy search interest

There is not enough data for TX200 CAR-Treg therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TX200 CAR-Treg therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SB-525 gene therapy to provide analysis

Correlation between past revenue and SB-525 gene therapy search interest

There is not enough data for SB-525 gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SB-525 gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for BIVV003 sickle cell disease to provide analysis

Correlation between past revenue and BIVV003 sickle cell disease search interest

There is not enough data for BIVV003 sickle cell disease to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for BIVV003 sickle cell disease to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Sangamo Therapeutics partnerships to provide analysis

Correlation between past revenue and Sangamo Therapeutics partnerships search interest

There is not enough data for Sangamo Therapeutics partnerships to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Sangamo Therapeutics partnerships to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for SGMO
Company name: Sangamo Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-11T20:05:00Z

GlobeNewswire
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

2026-04-30T12:05:00Z

GlobeNewswire
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

2026-04-29T12:05:00Z

GlobeNewswire
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

2026-03-30T20:01:00Z

GlobeNewswire
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

2026-03-09T12:05:00Z

GlobeNewswire
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

2026-02-10T11:51:55Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

2026-02-03T21:05:00Z

GlobeNewswire
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposiumâ„¢ 2026

2026-02-03T14:10:43Z

GlobeNewswire
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

2025-12-18T13:05:00Z

GlobeNewswire
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

2025-12-02T13:05:00Z

GlobeNewswire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

2025-11-21T13:05:00Z

GlobeNewswire
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

2025-11-07T12:24:35Z

Analyst Upgrades
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

2025-11-06T13:01:00Z

GlobeNewswire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

2025-10-30T20:01:00Z

GlobeNewswire
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

2025-10-09T18:49:05-04:00

SEC
3 Form - Initial statement of beneficial ownership of securities - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)